Promise-O2: Influence of Oxygen on Perioperative Outcome in Patients Undergoing General Anaesthesia for Elective Non-cardiac Surgery

Sponsor
University Hospital Inselspital, Berne (Other)
Overall Status
Recruiting
CT.gov ID
NCT04808401
Collaborator
(none)
110
1
4
30.8
3.6

Study Details

Study Description

Brief Summary

The purpose of this study is to investigate the impact of supraphysiologic oxygen (hyperoxia) on myocardial function in anaesthetized patients undergoing non-cardiac vascular surgery.

Condition or Disease Intervention/Treatment Phase
N/A

Detailed Description

Up to 110 patients with either proven coronary artery disease (CAD) or two or more risk factors for CAD undergoing elective or non-emergent non-cardiac vascular surgery will be recruited. Three blood samples for levels of myocardial biomarkers will be obtained at different perioperative time points (before anaesthesia induction, 2 hours after skin closure and 24 hours after the end of the surgery). The three myocardial biomarkers investigated are high-sensitive Troponin T (hsTnT), N-terminal (NT)-pro hormone BNP (NT-proBNP) and heart-type fatty acid binding protein (H-FABP). In the timeframe shortly after the induction of anaesthesia and prior to the start of surgery, myocardial strain as a marker of cardiac function will be measured by transesophageal echocardiography (TEE). Echocardiography measurements will be acquired at two different oxygen states for each patient.The fraction of inspired oxygen (FiO2) will be adjusted to reach a normoxaemic state (FiO2=0.3) and a hyperoxic state (FiO2=0.8). Patients will be randomized to which oxygen level is investigated first. Thereafter, the patients are again randomly assigned to either the normoxaemic or the hyperoxic state for the remainder of the perioperative treatment until 2 hours after skin closure. Surgery will be performed as planned by the treating team. Differences in the perioperative levels of myocardial biomarkers at the different time points and their dynamics will be assessed. Echocardiography images will be analyzed in a blinded manner for cardiac function and systolic and diastolic strain parameters. The results will help anaesthesiologists to better weigh risks and benefits when selecting an inspired oxygen fraction in such patients, and will help to evaluate hyperoxia as a risk factor for myocardial injury.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
110 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Patients start with a crossover design undergoing both TEE images at normoxia and hyperoxia in random order and then are randomized a second time to receive either normoxia or hyperoxia for the remaining procedure in a parallel design.Patients start with a crossover design undergoing both TEE images at normoxia and hyperoxia in random order and then are randomized a second time to receive either normoxia or hyperoxia for the remaining procedure in a parallel design.
Masking:
Single (Outcomes Assessor)
Masking Description:
TEE images will be coded and analysed in batches at a later date by a blinded reader
Primary Purpose:
Other
Official Title:
Influence of Different Inspired Oxygen Fractions on Perioperative Myocardial Biomarkers, Myocardial Strain and Outcome in Patients Undergoing General Anaesthesia for Elective Non-cardiac Surgery: A Prospective Randomized Open-label Single Centre Pilot Study
Actual Study Start Date :
May 7, 2021
Anticipated Primary Completion Date :
Dec 1, 2022
Anticipated Study Completion Date :
Dec 1, 2023

Arms and Interventions

Arm Intervention/Treatment
Experimental: Normoxaemia First + Hyperoxia Procedure

Patients will undergo TEE imaging at normoxaemia (FiO2=0.3) first, and hyperoxia (FiO2=0.8) will be targeted second. After the image acquisition patients receive hyperoxic concentrations.

Drug: Oxygen
Two FIO2 settings during stable general anaesthesia resulting in normoxaemic and hyperoxic arterial oxygen partial pressures.
Other Names:
  • Medical gas
  • Experimental: Normoxaemia First + Normoxia Procedure

    Patients will undergo TEE imaging at normoxaemia (FiO2=0.3) first, and hyperoxia (FiO2=0.8) will be targeted second. After the image acquisition patients receive normoxic concentrations.

    Drug: Oxygen
    Two FIO2 settings during stable general anaesthesia resulting in normoxaemic and hyperoxic arterial oxygen partial pressures.
    Other Names:
  • Medical gas
  • Experimental: Hyperoxia First + Hyperoxia Procedure

    Patients will undergo TEE imaging at hyperoxia (FiO2=0.8) first, and normoxaemia (FiO2=0.3) will be targeted second. After the image acquisition patients receive hyperoxic concentrations.

    Drug: Oxygen
    Two FIO2 settings during stable general anaesthesia resulting in normoxaemic and hyperoxic arterial oxygen partial pressures.
    Other Names:
  • Medical gas
  • Experimental: Hyperoxia First + Normoxaemia Procedure

    Patients will undergo TEE imaging at hyperoxia (FiO2=0.8) first, and normoxaemia (FiO2=0.3) will be targeted second. After the image acquisition patients receive normoxic concentrations.

    Drug: Oxygen
    Two FIO2 settings during stable general anaesthesia resulting in normoxaemic and hyperoxic arterial oxygen partial pressures.
    Other Names:
  • Medical gas
  • Outcome Measures

    Primary Outcome Measures

    1. Difference in hsTnT from preoperative baseline [at 24 hours after surgery]

      ng/L

    Secondary Outcome Measures

    1. Incidence of myocardial injury in non-cardiac surgery (MINS) [at 24 hours after surgery]

      MINS is defined as an absolute change of hsTnT levels of at least 5ng/L from preoperative baseline or an hs-TnT level of at least 65ng/L

    2. Difference in high sensitive TnT from preoperative baseline [at 2 hours after surgery]

      ng/L

    3. Differences in N-terminal pro B-type natriuretic peptide (NT-proBNP) from preoperative baseline [at 2 hours and 24 hours after surgery]

      pg/ml

    4. Differences in heart type fatty acid binding protein (H-FABP) from preoperative baseline [at 2 hours and 24 hours after surgery]

      pg/ml

    5. Difference in myocardial time to peak strain between oxygen levels [Through study completion, within 1hour post-induction]

      Milliseconds (ms)

    6. Difference in myocardial strain rate between oxygen levels [Through study completion, within 1hour post-induction]

      Change in strain over time (/second)

    7. Difference in myocardial strain rate ratio between oxygen levels [Through study completion, within 1hour post-induction]

      Change in E/A ratio

    8. Difference in myocardial displacement between oxygen levels [Through study completion, within 1hour post-induction]

      Millimeters (mm)

    9. Difference in myocardial time to peak displacement between oxygen levels [Through study completion, within 1hour post-induction]

      Milliseconds (ms)

    10. Difference in myocardial velocities between oxygen levels [Through study completion, within 1hour post-induction]

      Change in displacement over time (millimeters/second)

    11. Difference in myocardial velocity ratio between oxygen levels [Through study completion, within 1hour post-induction]

      Change in E/A ratio

    12. Difference in peak twist [Through study completion, within 1hour post-induction]

      Degrees (°)

    13. Difference in peak torsion [Through study completion, within 1hour post-induction]

      Degrees/centimeter (°/cm)

    14. Difference in ejection fraction (EF) [Through study completion, within 1hour post-induction]

      Percent (%)

    15. Difference in chamber volumes [Through study completion, within 1hour post-induction]

      Millilitres (ml)

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • Written informed consent

    • Patients eligible for the study should be scheduled for elective or non-emergent non-cardiac vascular surgery under general anaesthesia with endotracheal intubation, and have either

    • proven CAD and will undergo high- or intermediate surgical risk procedure according to European (European Society of Cardiology, ESC / European Society of Anaesthesiology and Intensive Care, ESAIC) guidelines on non-cardiac surgery.

    or

    • two or more risk factors for CAD and will undergo high- or intermediate surgical risk procedures according to European ESC/ESAIC guidelines on non-cardiac surgery.
    Exclusion Criteria:
    • Acute coronary event 30 days before surgery

    • Acute congestive heart failure

    • Hemodynamic instability before induction of aneasthesia (vasopressor or inotrope infusion since hospitalization for index surgery)

    • Atrial fibrillation or other severe arrhythmia

    • Severe pulmonary disease (dependent on oxygen therapy or the Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage 4 or severe carbon monoxide diffusion impairment or severe pulmonary hypertension)

    • Preoperative oxygen saturation (SpO2) below 90% on room air

    • Increased risk of oxygen toxicity (e.g., chemotherapy for malignancy within 3 months, bleomycin treatment, airway laser surgery)

    • Scheduled surgery in the thoracic cavity

    • ICU admission for respirator weaning and delayed extubation

    • Pre-existing surgical site infection (SSI)

    • Current active signs of systemic inflammatory response syndrome (SIRS) or sepsis according The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)

    • Pregnancy

    • Emergency surgery (to be performed within less than 12 hours of scheduling)

    • Ambulatory surgery

    • Baseline hs-TnT level elevated above 65ng/L

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Bern University Hospital, Inselspital Bern Switzerland 3010

    Sponsors and Collaborators

    • University Hospital Inselspital, Berne

    Investigators

    • Principal Investigator: Dominik P Guensch, MD, Bern University Hospital, Inselspital
    • Principal Investigator: Jan-Oliver Friess, MD, Bern University Hospital, Inselspital

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    University Hospital Inselspital, Berne
    ClinicalTrials.gov Identifier:
    NCT04808401
    Other Study ID Numbers:
    • 2020_02560
    First Posted:
    Mar 22, 2021
    Last Update Posted:
    Sep 30, 2021
    Last Verified:
    May 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by University Hospital Inselspital, Berne
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 30, 2021